OREX up +27.27% percent right now. $OREX High is a

OREX up +27.27% percent right now. $OREX High is at 4.88 and the Low 4.04 with current volume of 5,295,252.

Recent News posted below.

OREX Orexigen Therapeutics Recent Headline News

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - 1 hr 9 mins ago

OREX: 5.03 (+1.18), VVUS: 3.25 (-0.08), ARNA: 4.31 (+0.05)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 34 mins ago

UCP: 11.96 (-1.83), JRJC: 6.16 (+0.65), NAVB: 1.02 (-0.20), SANW: 3.81 (+0.73), PLPM: 1.62 (+0.25), RYN: 28.85 (-5.05), INFU: 3.01 (-0.48), LIOX: 5.47 (+0.73), DY: 27.85 (-3.02), MTZ: 25.17 (-3.46), CGIX: 6.95 (+0.95), MUX: 1.25 (-0.16), OREX: 5.03 (+1.18), URRE: 2.60 (+0.66), ACHN: 12.61 (+2.50), REN: 2.86 (-0.75), MPO: 3.41 (+0.30), AKBA: 9.35 (-1.35), TRX: 1.02 (-0.20), PLNR: 7.60 (+1.20)

Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - 2 hrs 6 mins ago
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 5.03 (+1.18)

Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - 2 hrs 42 mins ago

OREX: 5.03 (+1.18)

Orexigen ups earnings by 161% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:16AM CST

OREX: 5.03 (+1.18)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.03 (+1.18), VVUS: 3.25 (-0.08), ARNA: 4.31 (+0.05)

Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - Mon Nov 10, 9:33AM CST
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 5.03 (+1.18)

Orexigen Beats The Street On Milestone Payments
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 8:21AM CST

OREX: 5.03 (+1.18)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST

PT: 1.63 (+0.11), GPRO: 76.07 (-2.99), OREX: 5.03 (+1.18), GOGO: 18.10 (+1.46), JRJC: 6.16 (+0.65), UEC: 1.87 (+0.15), ACHN: 12.61 (+2.50), ARQL: 1.15 (+0.09), CMCM: 20.66 (+0.46), IBIO: 1.23 (+0.07), DF: 16.26 (+1.84)

Orexigen Therapeutics (OREX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:25AM CST

OREX: 5.03 (+1.18)

Orexigen Therapeutics beats by $0.22, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:08AM CST

OREX: 5.03 (+1.18)

Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for the third quarter ended September 30, 2014.
OREX: 5.03 (+1.18)

Critical Alerts For Stratasys, Orexigen Therapeutics, YY, Workday and Hong Kong Television Network Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SSYS, OREX, YY, WDAY and HKTV.
OREX: 5.03 (+1.18), YY: 82.08 (+2.58), WDAY: 95.30 (+0.74), SSYS: 104.60 (+1.53), HKTV: 11.11 (+0.24)

Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse Healthcare Conference in Phoenix. The presentation is scheduled for Tuesday, November 11th at 2:00 p.m. Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.03 (+1.18)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.03 (+1.18), VVUS: 3.25 (-0.08), ARNA: 4.31 (+0.05)

Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Tue Nov 04, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
OREX: 5.03 (+1.18)

Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST

OREX: 5.03 (+1.18), ARNA: 4.31 (+0.05)

Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
PR Newswire - Fri Oct 31, 7:30AM CDT
Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center.
OREX: 5.03 (+1.18)

Orexigen Therapeutics Has Substantial Upside For Bull Investors
L&F Capital Management - at Seeking Alpha - Wed Oct 29, 7:27AM CDT

OREX: 5.03 (+1.18)

Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 5.03 (+1.18), ARNA: 4.31 (+0.05)